Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.European Journal of Cancer (Oxford, England : 1990)|September 9, 2022
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based studyLennard Y W Lee, Maria C Ionescu, Thomas Starkey, et al.JAMA Oncology|December 22, 2022
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional EvaluationLennard Y W Lee, Michael Tilby, Thomas Starkey, et al.Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.Nature Medicine|March 1, 2022
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaKarla A Lee, Andrew Maltez Thomas, Laura A Bolte, et al.Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.The Oncologist|May 20, 2026
Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy CombinationsSara Elena Rebuzzi, Aruni Ghose, Sarah Rudman, et al.Scientific Reports|July 25, 2023
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)Thomas Starkey, Maria C Ionescu, Michael Tilby, et al.Journal of the National Cancer Institute|April 13, 2022
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid RegistryAlessio Cortellini, Alessandra Gennari, Fanny Pommeret, et al.The Lancet. Oncology|April 30, 2021
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Adam G Laing, Miguel Muñoz-Ruiz, et al.Pageof 7